Trial site
Hospital Araújo Jorge
Goiânia, 74605070, BrazilNot linked to an institution yet
- 12running trials
- 5closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Completed5 trials
- Recruiting2 trials
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche9 trials
- AstraZeneca2 trials
- Tolmar Inc.2 trials
- Eisai Inc.1 trial
- Eli Lilly and Company1 trial
- and 2 more
Running trials
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: Ruffo Freitas-Junior (principal investigator)
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239· Phase 3· Hoffmann-La Roche· Source
Enrolling by invitation
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
NCT05645536· Phase 3· Tolmar Inc.· Source
Active, not recruiting
Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System
NCT05306600· Hospital Moinhos de Vento· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT04906395· Phase 3· Tolmar Inc.· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353· Phase 3· AstraZeneca· Source
Active, not recruiting
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error